Gene Therapy Market Size Report 2032: Market Porter's Five Forces Analysis, Market Access, Market Drivers & Barriers, Market Restraints and Market Opportunities

DelveInsight's Gene Therapy Market Insights Report 2032 provides the current and forecast market analysis, individual leading Gene Therapy Companies market shares, challenges, Gene Therapy Market Drivers, barriers, trends, and key market Gene Therapy companies in the market.

To read more about the latest highlights related to the Gene Therapy Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Gene Therapy Market Report
• The Global Gene Therapy Market was valued at USD 8,570.28 million in 2024, growing at a CAGR of 19.25% during the forecast period from 2025 to 2032 to reach USD 34,933.71 million by 2032.
• The leading Gene Therapy Companies such as Abiomed, Inc., Asahi Kasei Corporation, Abbott Laboratories, Berlin Heart GmbH, Jarvik Heart, Inc., Medtronic Plc., Terumo Corporation, Evaheart, Inc., Calon Cardio, SynCardia Systems LLC, Cardiobridge Gmbhand, LivaNova, Inc., Cirtec, CorWave SA, FineHeart, ReliantHeart Inc., and others.
• North America is expected to account for the highest proportion of the gene therapy market in 2024, out of all regions. This can be ascribed to its advanced healthcare infrastructure, strong research and development capabilities, and substantial financial investments in innovative biopharmaceuticals.

To know more about why North America is leading the market growth in the Gene Therapy Market, get a snapshot @ Gene Therapy Market Outlook- https://www.delveinsight.com/sample-request/gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gene Therapy Market Dynamics
According to data from the Haemophilia Foundation Australia (2024), over 7,400 individuals in Australia were diagnosed with bleeding disorders. Globally, haemophilia affected approximately 1 in 6,000-10,000 males, with haemophilia A occurring in 1 in 6,000 males and haemophilia B in 1 in 26,000 males. An estimated 830,895 individuals worldwide had haemophilia, including about 282,266 with severe cases. Gene therapy offers a promising alternative by targeting the root cause of the disease through the delivery of functional genes capable of producing the missing clotting factors (Factor VIII for haemophilia A and Factor IX for haemophilia B). For example, therapies like BioMarin's Roctavian for haemophilia A and UniQure's Hemgenix for haemophilia B have shown the potential to reduce or eliminate the need for factor replacement therapy, improve quality of life, and address underlying genetic defects. Thus, the high global prevalence of haemophilia can significantly boost the overall market of gene therapy across the globe.

Gene Therapy Market Segment Analysis
Gene Therapy Market by Vector Type (Viral and Non-Viral), Delivery Type (Ex Vivo and In Vivo), Indication (Neurological, Oncological, Hematological, Ophthalmological, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). In the vector-type segment of the gene therapy market, the viral category is expected to hold a significant share in 2024. Viral gene therapy has become a significant driver in boosting the overall market of gene therapy due to its effectiveness in delivering therapeutic genes into target cells with precision and efficiency. The ability of viral vectors to transport therapeutic payloads to specific cells is pivotal in treating a variety of diseases, including rare genetic disorders, hemophilia, inherited blindness, and certain cancers.

Get a sneak peek at the Gene Therapy Market Dynamics @ Gene Therapy Market Dynamics Analysis- https://www.delveinsight.com/sample-request/gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gene Therapy Companies
Abiomed, Inc., Asahi Kasei Corporation, Abbott Laboratories, Berlin Heart GmbH, Jarvik Heart, Inc., Medtronic Plc., Terumo Corporation, Evaheart, Inc., Calon Cardio, SynCardia Systems LLC, Cardiobridge Gmbhand, LivaNova, Inc., Cirtec, CorWave SA, FineHeart, ReliantHeart Inc., and others.

Gene Therapy Market Drivers
The rising prevalence of genetic and rare diseases has driven demand for innovative treatments, positioning gene therapy as a promising solution. This demand is supported by the rapid expansion of the gene therapy pipeline, which includes numerous clinical trials and advanced therapies targeting conditions previously considered untreatable. Additionally, strategic activities such as mergers, acquisitions, and partnerships among key players have accelerated research, development, and commercialization efforts, collectively fostering innovation and boosting the overall market for gene therapy globally. Thus, all the factors mentioned above collectively contribute to the positive growth of the gene therapy market during the forecast period from 2025 to 2032.

Which MedTech key players in the Gene Therapy Market are set to emerge as the trendsetter explore @ Gene Therapy Companies- https://www.delveinsight.com/sample-request/gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gene Therapy Market Report
• Coverage- Global
• Forecast Period- 2025-2032
• Gene Therapy Companies- Abiomed, Inc., Asahi Kasei Corporation, Abbott Laboratories, Berlin Heart GmbH, Jarvik Heart, Inc., Medtronic Plc., Terumo Corporation, Evaheart, Inc., Calon Cardio, SynCardia Systems LLC, Cardiobridge Gmbhand, LivaNova, Inc., Cirtec, CorWave SA, FineHeart, ReliantHeart Inc., and others.

Interested in knowing the Gene Therapy Market by 2032? Click to get a snapshot of the Gene Therapy Market Trends- https://www.delveinsight.com/sample-request/gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Gene Therapy Market Report Introduction
2. Gene Therapy Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Gene Therapy Market Key Factors Analysis
6. Gene Therapy Market Porter's Five Forces Analysis
7. Gene Therapy Market Assessment
8. Gene Therapy Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.